Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea
The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
1. A method for the treatment of rosacea comprising administering to a subject having rosacea, an effective amount of a 2,5-dihydroxybenzene derivative selected from the group consisting of:
5-hydroxy-2-{[(4-methylphenyl)sulfonyl]oxy}benzenesulfonic acid;
2-hydroxy-5-{[(4-methylphenyl)sulfonyl]oxy}benzenesulfonic acid;
2,5-bis{[(4-methylphenyl)sulfonyl]oxy}benzenesulfonic acid;
2-(acetyloxy)-5-hydroxybenzenesulfonic acid;
5-(acetyloxy)-2-hydroxybenzenesulfonic acid;
2,5-bis(acetyloxy)benzenesulfonic acid;
and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the 2,5-dihydroxybenzene derivative is selected from: 2-(acetyloxy)-5-hydroxybenzenesulfonic acid; 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid and 2,5-bis(acetyloxy)benzenesulfonic acid.
3. The method of claim 1 , wherein the 2,5-dihydroxybenzene derivative is administered topically.
4. The method of claim 3 , wherein the 2,5-dihydroxybenzene derivative is administered orally, buccally, transdermally, by inhalation, rectally, intraocularly, or otically.
5. The method of claim 1 , further comprising administration of at least one additional therapeutic agent.
6. The method of claim 5 , wherein the at least one additional therapeutic agent is selected from the group consisting of: a steroid; a retinoid; an antimicrobial compound; an antioxidant; an anti-inflammatory compound; a vitamin D analog; salicylic acid; an endothelin antagonist; an immunomodulating agent; an angiogenesis inhibitor; an inhibitor of FGF, VEGF, EGF or HGF; an inhibitor of an EGF, FGF, VEGF or HGF receptor; a tyrosine kinase inhibitor; a protein kinase C inhibitor; metronidazole; dapsone; a vasoconstricting agent; and a combination of two or more thereof.
7. The method of claim 6 , wherein the at least one additional therapeutic agent is metronidazole.
8. The method of claim 3 , wherein the 2,5-dihydroxybenzene derivative is administered at least once per week.
9. The method of claim 8 , wherein the 2,5-dihydroxybenzene derivative is administered at least once per day.
10. The method of claim 9 , wherein the 2,5-dihydroxybenzene derivative is administered at least twice per day.
11. The method of claim 3 , wherein the 2,5-dihydroxybenzene derivative is present in a pharmaceutical composition in an amount of about 1% w/w to about 15% w/w.
12. The method of claim 3 , wherein the 2,5-dihydroxybenzene derivative is administered over a period of at least about one week.
13. The method of claim 12 , wherein the 2,5-dihydroxybenzene derivative is administered over a period of at least about four weeks.
14. The method of claim 1 , wherein the rosacea is selected from the group consisting of: erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea.